Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 19, 2015

Keywords

ClinConnect Summary

This clinical trial is looking at how changes in our DNA might be related to high blood pressure in patients with breast cancer who are receiving a treatment called bevacizumab. Researchers will analyze DNA samples from patients who experienced severe high blood pressure during their treatment and compare them to samples from those who did not. By doing this, they hope to find specific changes in the DNA that could help explain why some patients develop this side effect while others do not.

To participate in this study, you need to be a European American patient with available DNA, and you should have either experienced severe high blood pressure from bevacizumab or not developed high blood pressure at all after completing your treatment. If you join the study, you can expect to provide a DNA sample and help researchers learn more about the connection between genetics and hypertension in breast cancer patients. This could ultimately lead to better understanding and management of treatment side effects in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • European American patients with deoxyribonucleic acid (DNA) available and designated case or control
• • Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab
• • Patients who did not develop hypertension following a full course of treatment with bevacizumab